IP Library Patent Application 12143002
Patent Application
App. No. 12/143,002

METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/143,002
Abstract

The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.

Claims (4)

1 . A formulation comprising an isolated double stranded nucleic acid capable of reducing the expression of a target gene comprising

a first oligonucleotide strand that is 25-30 nucleotides in length and contains 1-3 DNA bases on the 3′ end of the first oligonucleotide strand; and

a second oligonucleotide strand that is 25-30 nucleotides in length comprising an overhang domain and a primary domain wherein the overhang domain is comprised of modified RNA monomers and the primary domain is capable of hybridizing to the first oligonucleotide strand and is comprised of a combination of unmodified and modified monomers,

wherein said second oligonucleotide strand is sufficiently complementary to a target RNA along at least 19 nucleotides of said second oligonucleotide strand length to reduce target gene expression when said double stranded nucleic acid is introduced into a mammalian cell, wherein said double stranded nucleic acid is present in said formulation in an amount effective to reduce target gene expression when said double stranded nucleic acid is introduced into a mammalian cell and possesses greater potency than isolated 21mer siRNAs directed to the identical at least 19 nucleotides of said target RNA in reducing target gene expression when assayed in vitro in a mammalian cell at an effective concentration in the environment of a cell of 1 nanomolar or less.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 5, 2017
From: JPMORGAN CHASE BANK, N.A.
To: INTEGRATED DNA TECHNOLOGIES, INC.
Reel/Frame 043800/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2016
From: KIM, DONGHO; ROSSI, JOHN J.; BEHLKE, MARK A.
To: CITY OF HOPE; INTEGRATED DNA TECHNOLOGIES, INC.
Reel/Frame 039942/0740 →
SECURITY AGREEMENT Recorded Apr 26, 2010
From: INTEGRATED DNA TECHNOLOGIES, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 024286/0152 →
RELEASE OF SECURITY INTEREST Recorded Apr 23, 2010
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: INTEGRATED DNA TECHNOLOGIES, INC.
Reel/Frame 024278/0374 →
SECURITY AGREEMENT Recorded Jun 18, 2009
From: INTEGRATED DNA TECHNOLOGIES, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 022846/0023 →
CONFIRMATORY LICENSE Recorded Jun 11, 2009
From: CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022811/0221 →